

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Trump backs off the 100% pharma tariffs ultimatum
- Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- White House announces “TrumpRx,” a new prescription drug website
- U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs - Pulitzer-winning healthcare reporter Laurie McGinley on her shift to advocacy work with PACR